ALK-abello A/S Class B (AKBLF)
OTHER OTC:AKBLF
AKBLF Stock Chart & Stats
$33.60
-$2.05(-9.17%)
At close: 4:00 PM EST
$33.60
-$2.05(-9.17%)
Day’s Range― - ―
52-Week Range$26.65 - $43.30
Previous CloseN/A
Volume1.00
Average Volume (3M)33.00
Market Cap
$9.28B
Enterprise Value$41.49B
Total Cash (Recent Filing)$316.00M
Total Debt (Recent Filing)$990.00M
Price to Earnings (P/E)46.8
Beta0.55
Next Earnings
Aug 20, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.28
Shares Outstanding202,567,200
10 Day Avg. Volume100
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.47
Enterprise Value/Revenue7.27
Enterprise Value/Gross Profit11.28
Enterprise Value/Ebitda26.74
Forecast
1Y Price Target
$47.14Price Target Upside40.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ALK-abello News
AKBLF FAQ
What was ALK-abello A/S Class B’s price range in the past 12 months?
ALK-abello A/S Class B lowest stock price was $26.65 and its highest was $43.30 in the past 12 months.
What is ALK-abello A/S Class B’s market cap?
ALK-abello A/S Class B’s market cap is $9.28B.
When is ALK-abello A/S Class B’s upcoming earnings report date?
ALK-abello A/S Class B’s upcoming earnings report date is Aug 20, 2026 which is in 67 days.
How were ALK-abello A/S Class B’s earnings last quarter?
ALK-abello A/S Class B released its earnings results on May 04, 2026. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.263 by $0.046.
Is ALK-abello A/S Class B overvalued?
According to Wall Street analysts ALK-abello A/S Class B’s price is currently Undervalued.
Does ALK-abello A/S Class B pay dividends?
ALK-abello A/S Class B pays a Annually dividend of $0.248 which represents an annual dividend yield of N/A. See more information on ALK-abello A/S Class B dividends here
What is ALK-abello A/S Class B’s EPS estimate?
ALK-abello A/S Class B’s EPS estimate is 0.23.
How many shares outstanding does ALK-abello A/S Class B have?
ALK-abello A/S Class B has 202,567,200 shares outstanding.
What happened to ALK-abello A/S Class B’s price movement after its last earnings report?
ALK-abello A/S Class B reported an EPS of $0.31 in its last earnings report, beating expectations of $0.263. Following the earnings report the stock price went up 7.001%.
Which hedge fund is a major shareholder of ALK-abello A/S Class B?
Currently, no hedge funds are holding shares in AKBLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ALK-abello A/S Class B
ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
AKBLF Company Deck
AKBLF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: the company delivered strong Q1 financial results (18% revenue growth, 22% EBIT growth, 32% EBIT margin), achieved a major tablet sales milestone (over DKK 1 billion in a quarter), upgraded full-year guidance, reported robust regional and anaphylaxis product growth, and announced a successful Phase II peanut trial and key neffy regulatory approvals. Notable challenges include higher capacity costs (+23%), international shipment phasing (notably Japan) causing a -17% tablet decline in some markets, partner-related lower-margin revenue expected to rise, neffy market-access hurdles (UK local formularies, U.S. access), potential German pricing/rebate risk, and planned increased R&D/commercial spending for upcoming phases. Overall, the positives materially outweigh the negatives given upgraded guidance, cash generation, and strategic clinical progress.View all AKBLF earnings summariesAKBLF Stock 12 Month Forecast
Average Price Target
$47.14
▲(40.29% Upside)
Technical Analysis
―
Inovio Pharmaceuticals
―
Aclaris Therapeutics
―
Emergent Biosolutions
―
Novartis
―
Bristol-Myers Squibb
―
Ownership Overview
― Insiders
3.61% Mutual Funds
― Other Institutional Investors
90.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---